What Is The Long-Term Forecast For The Carbapenem-Based Antibiotics Market Growing At 5.7% CAGR?
Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors
#What CAGR And Valuation Are Anticipated For The Carbapenem-Based Antibiotics Market?#_x000D_
The market size of carbapenem-based antibiotics has seen stable growth in recent years. Its estimated value is set to increase from $4.6 billion in 2024 to $4.78 billion in 2025, reflecting a compound annual growth rate (CAGR) of 3.8%. The expansion during the historic period could be traced back to numerous factors like epidemics and pandemics, escalation of chronic diseases, development in healthcare infrastructure, swift rate of urbanization, and the occurrence of natural disasters and health emergencies._x000D_
_x000D_
In the coming years, the carbapenem-based antibiotics market is projected to experience significant growth. By 2029, it is estimated to reach a worth of “$5.97 billion”, growing at a CAGR of 5.7%. This growth during the projection period can be attributed to factors such as a rise in hospital-acquired infections, the emergence of multi-drug resistant strains, an aging populace, an increase in surgical procedures, the spread of infectious diseases, and shifting demographics. The forecast period is expected to witness trends of supply chain resilience and security, the development of alternative treatments, a shift towards outpatient settings, increased awareness of antimicrobial stewardship, and precision medicine approaches._x000D_
_x000D_
#Get A Free Sample Of The Report:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=12035&type=smp_x000D_
_x000D_
#What Underlying Factors Are Supporting The Carbapenem-Based Antibiotics Market Growth?#_x000D_
The rise in bacterial infections is anticipated to fuel the expansion of the carbapenem-based antibiotics market in the future. Bacterial infections, which are caused by tiny organisms capable of penetrating the body and leading to a spectrum of diseases and symptoms, are addressed by carbapenem-based antibiotics. These antibiotics are designed to tackle severe or multidrug-resistant bacterial infections, induced by both gram-positive and gram-negative bacteria. For instance, a report from the US-government-run Centers for Disease Control and Prevention in July 2024 stated that in 2023, 78% of all bacterial infections were identified by CIDTs in the given historical catchment area, with 46% diagnosed solely using CIDTs. Consequently, a heightened occurrence of bacterial infections propels the advancement of the carbapenem-based antibiotics market._x000D_
_x000D_
#Which Segment Accounts For The Largest Share In The Carbapenem-Based Antibiotics Market?#_x000D_
The carbapenem-based antibiotics market covered in this report is segmented – _x000D_
_x000D_
1) By Type: Meropenem, Imipenem, Doripenem, Tebipenem, Other Types_x000D_
2) By Indication: Intra-abdominal Infections, Urinary Tract Infections, Pneumonia, Bacterial Meningitis, Skin And Skin Structure Infections, Acute Pelvic Infections, Prophylaxis of Surgical Site Infection, Respiratory Tract Infections, Gynecological Infections, Other Indications _x000D_
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies_x000D_
_x000D_
Subsegments:_x000D_
1) By Meropenem: Meropenem Injection, Meropenem and Vaborbactam Combination, Meropenem for Pediatric Use _x000D_
2) By Imipenem: Imipenem and Cilastatin Combination, Imipenem and Relebactam Combination, Imipenem Monotherapy _x000D_
3) By Doripenem: Doripenem Injection, Doripenem for Complicated Infections _x000D_
4) By Tebipenem: Tebipenem for Oral Administration, Tebipenem Pediatric Formulations, Tebipenem for Resistant Infections _x000D_
5) By Other Types: Ertapenem, Panipenem, Faropenem, Combinations with Beta-Lactamase Inhibitors_x000D_
_x000D_
#Which Long-Term Trends Will Play A Crucial Role In The Carbapenem-Based Antibiotics Market?#_x000D_
The carbapenem-based antibiotics market is witnessing a growing trend in product innovations spearheaded by major market players to maintain their competitive edge. For instance, in August 2024, the UK’s National Health Service launched an innovative subscription model in partnership with the pharmaceutical industry to fight against antimicrobial resistance (AMR). Revealed on August 12, 2024, this unique approach allows pharmaceutical companies to earn a fixed annual amount—up to £20 million per medication—without consideration of prescription volumes, thus eliminating motivation for abuse. The project has an expected worth of about £1.9 billion over a span of 16 years, with a goal to promote the creation of new antibiotics by guaranteeing financial stability for pharmaceutical firms. This scheme, following a trial phase, contributes to the UK’s wider plan to address AMR, a major worldwide health risk that could result in millions of fatalities by 2050 if not handled properly. The NHS will give precedence to innovations that target critical pathogens as identified by the World Health Organization, enhancing its promise to effective antibiotic management whilst promoting innovation in antibiotic production._x000D_
_x000D_
#Who Are The Dominant Players In The Carbapenem-Based Antibiotics Market Today?#_x000D_
Major companies operating in the carbapenem-based antibiotics market include Pfizer Inc., Merck & Co. Inc., Fresenius Kabi LLC, GlaxoSmithKline Plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Meiji Holdings Co. Ltd., Sandoz International GmbH, Sumitomo Dainippon Pharma Co. Ltd., Shionogi & Co Ltd., Aurobindo Pharma Ltd., Acurx Pharmaceuticals LLC, Daewoong Pharmaceutical Co. Ltd., CeramTec GmbH, ACS Dobfar S.p.A, JW Pharmaceutical Corp, Centrient Pharmaceuticals Co, Spero Therapeutics Inc., Kopran Limited, Savior Lifetec Corporation, Flagship Biotech International Pvt. Ltd., Iterum Therapeutics plc, Cam Carbapenem-based antibiotics BV, Intelicure Lifesciences, Ikeda Corporation _x000D_
_x000D_
#Access The Complete Report Here:#_x000D_
_x000D_
#What Regional Factors Are Accelerating Growth In The Carbapenem-Based Antibiotics Market?#_x000D_
North America was the largest region in the Carbapenem-Based Antibiotics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carbapenem-based antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Customize Your Report Here:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=12035&type=smp_x000D_
_x000D_
#About The Business Research Company:#_x000D_
_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Asia +44 7882 955267 & +91 8897263534_x000D_
Europe +44 7882 955267_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
